Durch Arbeiten im Rechenzentrum kann die Erreichbarkeit am 20. und 21. April 2024 kurzfristig eingeschränkt sein.
Download
916.full.pdf 416,09KB
WeightNameValue
1000 Titel
  • Model-informed COVID-19 vaccine prioritization strategies by age and serostatus
1000 Autor/in
  1. Bubar, Kate |
  2. Kyle Reinholt |
  3. Stephen M. Kissler |
  4. Lipsitch, Marc |
  5. Cobey, Sarah |
  6. Grad, Yonatan |
  7. Larremore, Daniel |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-02-26
1000 Erschienen in
1000 Quellenangabe
  • 371(6532):916-921
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1126/science.abe6959 |
1000 Ergänzendes Material
  • https://science.sciencemag.org/content/371/6532/916/suppl/DC1 |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Limited initial supply of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine raises the question of how to prioritize available doses. We used a mathematical model to compare five age-stratified prioritization strategies. A highly effective transmission-blocking vaccine prioritized to adults ages 20 to 49 years minimized cumulative incidence, but mortality and years of life lost were minimized in most scenarios when the vaccine was prioritized to adults greater than 60 years old. Use of individual-level serological tests to redirect doses to seronegative individuals improved the marginal impact of each dose while potentially reducing existing inequities in COVID-19 impact. Although maximum impact prioritization strategies were broadly consistent across countries, transmission rates, vaccination rollout speeds, and estimates of naturally acquired immunity, this framework can be used to compare impacts of prioritization strategies across contexts.
1000 Sacherschließung
gnd 1206347392 COVID-19
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-1876-3132|https://frl.publisso.de/adhoc/uri/IEt5bGUgUmVpbmhvbHQ=|https://frl.publisso.de/adhoc/uri/U3RlcGhlbiBNLiBLaXNzbGVy|https://orcid.org/0000-0003-1504-9213|https://orcid.org/0000-0001-5298-8979|https://orcid.org/0000-0001-5646-1314|https://orcid.org/0000-0001-5273-5234
1000 Label
1000 Förderer
  1. BioFrontiers Institute, University of Colorado Boulder |
  2. National Institute of General Medical Sciences |
  3. Harvard T. H. Chan School of Public Health |
  4. National Cancer Institute |
1000 Fördernummer
  1. -
  2. 3U24GM132013-02S2
  3. -
  4. 1U01CA261277-01
1000 Förderprogramm
  1. Quantitative Biology (IQ Biology) Ph.D. program
  2. MIDAS Coordination Center (MIDASNI2020-2)
  3. Morris-Singer Fund for the Center for Communicable Disease Dynamics
  4. SeroNet program
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer BioFrontiers Institute, University of Colorado Boulder |
    1000 Förderprogramm Quantitative Biology (IQ Biology) Ph.D. program
    1000 Fördernummer -
  2. 1000 joinedFunding-child
    1000 Förderer National Institute of General Medical Sciences |
    1000 Förderprogramm MIDAS Coordination Center (MIDASNI2020-2)
    1000 Fördernummer 3U24GM132013-02S2
  3. 1000 joinedFunding-child
    1000 Förderer Harvard T. H. Chan School of Public Health |
    1000 Förderprogramm Morris-Singer Fund for the Center for Communicable Disease Dynamics
    1000 Fördernummer -
  4. 1000 joinedFunding-child
    1000 Förderer National Cancer Institute |
    1000 Förderprogramm SeroNet program
    1000 Fördernummer 1U01CA261277-01
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6427586.rdf
1000 Erstellt am 2021-05-19T11:56:36.200+0200
1000 Erstellt von 218
1000 beschreibt frl:6427586
1000 Bearbeitet von 218
1000 Zuletzt bearbeitet Thu Oct 27 08:29:24 CEST 2022
1000 Objekt bearb. Thu Oct 27 08:29:24 CEST 2022
1000 Vgl. frl:6427586
1000 Oai Id
  1. oai:frl.publisso.de:frl:6427586 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source